Danaher (NYSE:DHR) Director Teri List Sells 3,298 Shares of Stock

Danaher Corporation (NYSE:DHR) Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Teri List also recently made the following trade(s):

• On Friday, August 22nd, Teri List sold 2,778 shares of Danaher stock. The shares were sold at an average price of $211.06, for a total value of $586,324.68.

Danaher Price Performance

Shares of DHR traded down $2.93 during trading hours on Wednesday, hitting $222.58. The stock had a trading volume of 4,483,261 shares, compared to its average volume of 4,202,454. The stock has a market capitalization of $157.22 billion, a price-to-earnings ratio of 45.89, a P/E/G ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The company’s fifty day moving average is $206.70 and its two-hundred day moving average is $201.47. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.71 EPS. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is presently 26.39%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC acquired a new position in Danaher in the third quarter valued at approximately $25,000. WFA of San Diego LLC bought a new stake in shares of Danaher during the 2nd quarter valued at $26,000. Howard Hughes Medical Institute acquired a new position in shares of Danaher in the 2nd quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher in the 3rd quarter worth $27,000. Finally, TruNorth Capital Management LLC bought a new position in shares of Danaher in the 3rd quarter worth $28,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DHR shares. Evercore ISI raised their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 10th. Guggenheim reiterated a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Finally, Barclays boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.